Abstract
Breast cancer (BC) remains the most common malignant tumor site and the leading cause of cancer-related deaths in women despite the wide availability of screening programs and personalized treatment options. The BRIGHT study tested a genetic risk-based personalized BC screening service model in women younger than 50 years, using telemedicine and home-based testing. Participants underwent polygenic risk score and monogenic pathogenic variant testing. This type of screening model demonstrated feasibility, clinical utility, and acceptability. It has the potential to enhance BC screening programs, particularly for younger women and those at higher genetic risk, while avoiding unnecessary interventions for low-risk individuals.
Competing Interest Statement
PP has ownership in OU Antegenes. AP, KKK, SS, AP, JP, and NT are receiving salaries from OU Antegenes. PP, KO, AL, LL, LR (Laura Roht), SP, TK, AI, SU, KK, ATT, and NT are receiving salaries from the Tartu University Hospital.
Clinical Trial
ISRCTN29884654
Funding Statement
This project was supported via the EIT Health BRIGHT innovation activity (project #230121). EIT Health is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union. Views and opinions expressed are, however, those of the authors only and do not necessarily reflect those of the European Union or the EIT. Neither the European Union nor the granting authority can be held responsible for them. SP received support from the Estonian Research Council grant PSG774.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Estonian Committee on Bioethics and Human Research gave ethical approval for this work (permission number 1.1-12/1930). Ethics committee of the Portuguese Ethics Committee of the Lisbon Academic Medical Center gave ethical approval for this work (permission number 177/22). Ethics committee of the Swedish Ethical Review Authority gave ethical approval for this work (permission number 2022-03074-01).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All materials used for this study are included in the main or supplementary information files. The participants datasets generated and analyzed during the current study are not publicly available due to reasons of sensitivity but are available from the corresponding author upon reasonable request. Data are located in controlled access data storage at OU Antegenes.
Abbreviations
- BC
- breast cancer
- BRIGHT
- Be RIGHT with breast cancer risk management
- MPV
- monogenic pathogenic variant
- PRS
- polygenic risk score
- RR
- relative lifetime risk
- SNP
- single nucleotide polymorphism
